Press release
Encephalopathy Pipeline Outlook Report 2024 (Updated)
Encephalopathy Pipeline
Key Takeaways from the Encephalopathy Pipeline Report
• DelveInsight's Encephalopathy pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Encephalopathy treatment.
• The leading companies working in the Encephalopathy market include Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Q-State Biosciences Inc., Ocera Therapeutics, and others.
• Promising Encephalopathy Pipeline Therapies in the various stages of development include RLS-0071, TAK-935, VSL#3, Rifaximin SSD, AST-120, Ornithine Phenylacetate, Flortaucipir F18, ZX008 (Fenfluramine Hydrochloride), Standard Medical Therapy, Lactulose, HPN-100, and others.
• April 2024: Zogenix Inc. announced a study of Phase 3 clinical trials for ZX008 (Fenfluramine Hydrochloride). This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
• March 2024: Bausch Health Americas Inc. announced a study of Phase 3 clinical trials for Rifaximin SSD. Study RNLC3131 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.
Request a sample and discover the recent advances in Encephalopathy Treatment Drugs @ Encephalopathy Pipeline Report- https://www.delveinsight.com/sample-request/encephalopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Encephalopathy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Encephalopathy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Encephalopathy clinical trial landscape.
Encephalopathy Overview
Encephalopathy is a broad term used to describe abnormal brain function or brain structure. (Encephalo= brain + pathy= disorder). The abnormality may be transient, recurrent, or permanent. The loss of brain function may be reversible, static and stable, or progressive with increasing loss of brain activity over time.
Find out more about Encephalopathy Treatment Landscape @ Drugs for Encephalopathy Treatment- https://www.delveinsight.com/sample-request/encephalopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Encephalopathy Emerging Drugs Profile
• XEN496: Xenon Pharmaceuticals
XEN496, a Kv7 potassium channel opener, is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).Xenon has received Fast Track designation and Orphan Drug Designation for XEN496 for the treatment of seizures associated with KCNQ2-DEE from the U.S. Food and Drug Administration (FDA), as well as orphan medicinal product designation from the European Commission.
• AXA 1665: Axcella Health
AXA1665 is an EMM composition of 8 amino acids and derivatives that targets three key nodes: ammonia toxicity, amino acid imbalance, and muscle wasting. Asp and Orn are intended to promote the function of the urea cycle. AXA1665 is designed to support pathways related to ammonia handling: Asp and Orn promote the function of the urea cycle and improved muscle mass and function promote ammonia handling within skeletal muscle. Currently, the drug is in Phase II stage of development for the treatment of Hepatic Encephalopathy.
• RBX 7455: Rebiotix
Rebiotix Inc., a Ferring Company, has leveraged its clinical, manufacturing and regulatory experience with RBX2660 to develop the first of its kind non-frozen, room temperature stable oral microbiota-based formulation under the MRT™ drug platform, known as RBX7455.Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Hepatic Encephalopathy.
Encephalopathy Pipeline Therapeutics Assessment
The Encephalopathy pipeline report proffers an integral view of the Encephalopathy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Learn more about the emerging Encephalopathy Pipeline Therapies @ Encephalopathy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/encephalopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Encephalopathy Pipeline Report
• Coverage- Global
• Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Encephalopathy Companies- Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Q-State Biosciences Inc., Ocera Therapeutics, and others.
• Encephalopathy Pipeline Therapies- RLS-0071, TAK-935, VSL#3, Rifaximin SSD, AST-120, Ornithine Phenylacetate, Flortaucipir F18, ZX008 (Fenfluramine Hydrochloride), Standard Medical Therapy, Lactulose, HPN-100, and others.
Dive deep into rich insights for new drugs for Encephalopathy Treatment, Visit @ Encephalopathy Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/encephalopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Encephalopathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Encephalopathy- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. XEN496: Xenon Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RBX 7455: Rebiotix
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name; Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Encephalopathy Key Companies
21. Encephalopathy Key Products
22. Encephalopathy - Unmet Needs
23. Encephalopathy - Market Drivers and Barriers
24. Encephalopathy - Future Perspectives and Conclusion
25. Encephalopathy Analyst Views
26. Encephalopathy Key Companies
27. Appendix
For further information on the Encephalopathy Pipeline therapeutics, reach out to Encephalopathy Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/encephalopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Encephalopathy Pipeline Outlook Report 2024 (Updated) here
News-ID: 3457362 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Encephalopathy
Top Trends Transforming the Hepatic Encephalopathy Market Landscape in 2025: Inn …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
What Will the Hepatic Encephalopathy Industry Market Size Be by 2025?
The market size for hepatic encephalopathy has witnessed significant expansion in the past few years. The market, projected to rise from $1.72 billion in 2024 to $1.8 billion in 2025, is estimated to have a compound annual growth…
Top Factor Driving Hepatic Encephalopathy Market Growth in 2025: Rising Prevalen …
What industry-specific factors are fueling the growth of the hepatic encephalopathy market?
The upswing in liver disease incidences is predicted to fuel the hepatic encephalopathy market's expansion. Liver diseases, medical conditions that impact the liver's operation, are treatable with therapies like hepatic encephalopathy which can mitigate symptoms, slow the disease's advancement, boost liver performance, and trim down the recurrence of hepatic encephalopathy by better management of the root causes. This could…
Encephalopathy Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Endometrial Cancer Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Endometrial Cancer Pipeline Report
• Over 50+ Endometrial Cancer…
Hepatic Encephalopathy Treatment Market - Transforming hepatic encephalopathy ca …
Newark, New Castle, USA: The "Hepatic Encephalopathy Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hepatic Encephalopathy Treatment Market: https://www.growthplusreports.com/report/hepatic-encephalopathy-treatment-market/8818
This latest report researches the industry structure,…
Hepatic Encephalopathy Treatment Market - Driving Progress, Inspiring Hope: Lead …
Newark, New Castle, USA - new report, titled Hepatic Encephalopathy Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Hepatic Encephalopathy Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Hepatic Encephalopathy Treatment market. The report offers an overview of…
Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018 - ResearchByMa …
"Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018", provides an overview of the Chronic Traumatic Encephalopathy (CTE) (Central Nervous System) pipeline landscape.
Chronic Traumatic Encephalopathy (CTE) is a degenerative brain disease found in athletes, military veterans, and others with a history of repetitive brain trauma. Symptoms include loss of consciousness, headache, drowsiness, convulsions and slurred speech, nausea or vomiting and unusual behavior. Risk factors include repeated exposure to traumatic brain…
